In this interview, James Foster, chairman and CEO of Charles River Laboratories, discusses the reopening of the Shrewsbury, Massachusetts facility and Charles River’s partnership with AstraZeneca.
Charles River has announced a $212 million purchase of British company Celsis International. The company specializes in providing systems that are used to detect harmful contaminants in substances ranging from prescription drugs to consumer beverages.
The acquisition of Celsis International Ltd. complements Charles River Endotoxin and Microbial Detection’s (EMD) position as a leading provider of rapid endotoxin testing and bacterial identification for biopharmaceutical manufacturing, and creates the most comprehensive solution for rapid quality control testing of biopharmaceutical and consumer products.
Charles River announced that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject to customary closing adjustments.
Charles River is absorbing Celsis, a Chicago-headquartered company that tests drugs and consumer products for contamination. Celsis works with pharma, beauty companies and the food industry, touting itself as a provider of rapid testing systems that allow clients to quickly get their products onto the market.
Charles River Labs announced Thursday that it had signed an agreement to acquire the bacteria detection company Celsis International Ltd. for $212 million. This acquisition will strengthen the Wilmington company’s market position in testing the safety of drugs and consumer products.
The Atlantic horseshoe crab and Charles River have mutually benefitted from one another for the last thirty years. In a recent article, John Dubczak, General Manager of Endotoxin and Microbial Detection, spoke about the value of the horseshoe crab and the efforts that Charles River has undergone in order to protect and preserve this natural resource.
With cancer immunotherapy becoming a major focus of oncology research over the past several years, the next blockbuster drug will likely target the immune system. By exploiting model systems, such as syngeneic tumors, and identifying the next major variable associated with immunologically driven elimination of tumor cells, the promise of new immunotherapies can be realized.
The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative came about after the realization that the current cardiac toxicity testing paradigm is too conservative, keeping potentially beneficial drugs off the market and away from patients who need them. At the same time, current methods are relatively poor predictors of drug-induced cardiac arrhythmias.
Ultra high-performance liquid chromatography (UHPLC) can increase data reproducibility and instrument capacity in the medicinal chemistry laboratory setting.